玻璃体内注射贝伐单抗治疗糖尿病性黄斑水肿的短期疗效

EFFICACY OF INTRAVITREAL BEVACIZUMAB FOR SHORT-TERM TREATMENT OF DIABETIC MACULAR EDEMA

目的评价玻璃体内注射贝伐单抗治疗糖尿病性黄斑水肿(DME)的短期疗效。方法收集门诊确诊糖尿病性持续性黄斑水肿患者30例,同时接受玻璃体腔注射贝伐单抗(1.25mg/0.05ml),治疗前和玻璃体腔注射后1周、4周定期进行门诊回访观察,包括:国际标准对数视力表检查最佳矫正视力(BC-VA)、光学相干断层成像(OCT)计算中心视网膜平均厚度。结果术后第一周最佳矫正视力提高2行以上有9只眼(30%,P<0.05),第四周有11只眼(36.7%,P<0.05)。平均最佳矫正视力统计学有提高;平均中心视网膜厚度(CRT)治疗前为(411±170)μm:治疗后1周(349±102)μm(P<0.05),治疗后4周(360±159)μm(P<0.05)。观察期间没有发现与注射药物相关的眼科并发症。结论对糖尿病性黄斑水肿进行玻璃体腔注射贝伐单抗后,短期观察最佳矫正视力和中心视网膜厚度均有变化。

Objective To explore the efficacy of intravitreal injections of bevacizumab for diabetic macular edema（DME） in the short-term.Methods Medical records of 30 eyes of 25 patients who underwent intravitreal injections of bevacizumab for persistent diabetic macular edema were reviewed retrospectively.All eyes received intravitreal injections of bevacizumab（1.25mg/0.05ml）.The clinical course of best-corrected visual acuity（BCVA） using a logarithm of the minimum angle of resolution chart,and averaged foveal retinal thickness using an optical coherence tomography（OCT） were monitored for up to four weeks after the injection.Results BCVA at the first week improved by two lines or more in nine eyes（30%,P0.05） and in eleven eyes（36.7%,P0.05） at four weeks.Significant improvement in the mean BCVA from baseline was observed.Mean central retinal thicknesses（CRT） were 411±170μm at baseline,349±102μm at one week after the injection（P0.05）,and 360±159μm at four weeks（P0.05）.after the injection,significant regression of macular edema was seen.No complications such as severe vision loss,endophthalmitis,or systemic events developed.Conclusion This study shows changes in BCVA and CRT were observed in the short-term observation after the intravitreal injection of bevacizumab for DME.